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Abstract
Background: Accumulating evidence suggested that epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC)
characteristics, both of which contribute to tumor invasion and metastasis, are interrelated with miR-21. MiR-21 is one of the
important microRNAs associated with tumor progression and metastasis, but the molecular mechanisms underlying EMT
and CSC phenotype during miR-21 contributes to migration and invasion of breast cancer cells remain to be elucidated.
Methodology/Principal Findings: In this study, MDA-MB-231/anti-miR-21 cells were established by transfected hsa-miR-21
antagomir into breast cancer MDA-MB-231 cells. EMT was evaluated by the changes of mesenchymal cell markers (N-
cadherin, Vimentin, and alpha-SMA), epithelial cell marker (E-cadherin), as well as capacities of cell migration and invasion;
CSC phenotype was measured using the changes of CSC surface markers (ALDH1 and CD44), and the capacity of
sphereforming (mammospheres). We found that antagonism of miR-21 reversed EMT and CSC phenotype, accompanied
with PTEN up-regulation and AKT/ERK1/2 inactivation. Interestingly, down-regulation of PTEN by siPTEN suppressed the
effects of miR-21 antagomir on EMT and CSC phenotype, confirming that PTEN is a target of miR-21 in reversing EMT and
CSC phenotype. The inhibitors of PI3K-AKT and ERK1/2 pathways, LY294002 and U0126, both significantly suppressed EMT
and CSC phenotype, indicating that AKT and ERK1/2 pathways are required for miR-21 mediating EMT and CSC phenotype.
Conclusions/Significance: In conclusion, our results demonstrated that antagonism of miR-21 reverses EMT and CSC
phenotype through targeting PTEN, via inactivation of AKT and ERK1/2 pathways, and showed a novel mechanism of which
might relieve the malignant biological behaviors of breast cancer.
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Introduction
Epithelial-mesenchymal transition (EMT) is associated with
increased aggressiveness and metastasis in carcinomas, including
breast cancer, as it allows cells to migrate and invade surrounding
issues and escape into the bloodstream, en route to establishing
metastasis. Once these metastatic cells reach their destination, they
can undergo mesenchymal- epithelial transition (MET) to establish
secondary tumors, resulting in cancer spreading and treatment
failure [1–3]. On the molecular level, cells undergoing EMT
towards a more mesenchymal phenotype involves loss or lowered
the expression of epithelial markers such as E-cadherin, and
increased the expression of mesenchymal markers such as N-
cadherin, Vimentin, and alpha-SMA [2,4,5]. There are studies
suggested that EMT in breast cancer is tightly linked to the basal-
like phenotype breast cancer subgroup and cancer stem cells
(CSCs) [6–8].
CSCs are predicted to be critical drivers of tumor progression
due to CSC characteristics including self-renewal capacity,
limitless proliferative potential and metastasis potential, suggest-
ing that targeting CSC characteristics would likely eliminate
CSCs which are the ‘‘seeds’’ of tumor recurrence and
metastasis. Although the CSC hypothesis suggests that tumors
can arise from stem/progenitor cells, studies from many
laboratories demonstrated that EMT can endow cells which
possess CSC characteristics as well as a more motile invasive
phenotype [7–10]. Previously studies have been confirmed that
breast cancer contains a CSC-compartment [11–13], which can
be enriched by purifying Aldehyde dehydrogenase 1 (ALDH1)-
positive cells [13] or CD44
+/CD24
2/low cells [11] by sorting,
and also by purifying sphereforming cells (mammospheres) from
parental cells [12]. There are studies demonstrated that EMT
phenotype is highest in the CD44
+/CD24
2/low breast cancer
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39520CSCs (7), and CSCs enriched from breast tumors and
metastatic breast pleural effusions express markers similar to
cells that have undergone an EMT [7,14]. Similarly, EMT and
CSC markers are also frequently associated with breast cancers
that have a propensity to metastasis, such as basal-like
phenotype breast cancer subgroup [15] and metaplastic [16]
breast cancers.
MicroRNAs (miRNAs) are a family of small non-coding RNA
molecules which regulate gene expression by base pairing to the
39-UTR of the target mRNA. Recently, a series of miRNAs
have been shown to play critical roles in the progression and
metastasis of human malignancy [17,18], including breast
cancer. MiR-21 is one of the first miRNAs detected in the
human genome, which also is one of miRNAs known to be up-
regulated in all types of human malignancies [19]. Recent
studies indicated that several tumor suppressors including
phosphatase and tensin homolog deleted on chromosome ten
(PTEN) [20], tumor suppressor gene tropomyosin 1 (TPM1)
[21], programmed cell death 4 (PDCD4) [22], maspin [23], and
matrix metalloproteinases inhibitors RECK and TIMP3 [24]
were targets of miR-21, suggesting that miR-21 is an important
oncogenic miRNA which is closely related to tumor growth and
metastasis.
There are studies demonstrated that miR-21 is an important
component of the cellular signaling circuitry that regulates the
EMT program [25–27], as well as associates with CSC signatures
[26,28], suggesting that miR-21 plays a key role in the process of
EMT and acquisition of CSC characteristics, which consistent
with our previously study [29], but the underlying mechanisms
remain unclear.
Recent studies have demonstrated that miR-21 increases
tumor cell proliferation, migration, and invasion through
Figure 1. Antagonism of miR-21 reversed EMT phenotype, as well as decreased cell migration and invasion. MDA-MB-231 cells were
transfected with hsa-miR-21 antagomir or hsa-miR-21 antagomir control at a final concentration of 50 nmol for 48 h. (A) MDA-MB-231 cells were
treated with hsa-miR-21 antagomir decreased the expression of miR-21, as compared to control groups (n1=n2=3; p=0.0015), by real-time RT-PCR
analysis. (B-E) The mRNA levels of mesenchymal biomarkers (N-cadherin, Vimentin and alpha-SMA) and epithelial biomarker (E-cadherin) in MDA-MB-
231/anti-miR-21 cells and MDA-MB-231/control cells, as measured by real-time RT-PCR analysis. The real-time RT-PCR reactions were performed in
a2 0ml reaction volume in triplicate, simultaneously. (F, G) The relative protein levels of EMT markers in indicated cells were shown by Western blot
analysis, and bands were semi-quantified using ImageJ software. Beta-actin was used as loading control. (H, I) The migratory and invasive properties
of indicated cells were tested in migration and invasion assay in Transwell inserts. Penetrated cells were counted and analyzed in histogram. Data
represent at least three experiments done in triplicate. (*indicates p,0.05;
w indicates p,0.001).
doi:10.1371/journal.pone.0039520.g001
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antagonist of phosphatidylinotidol 3-kinase (PI3K) by removing
the 39-UTR phosphate of phosphatidylinositol 3,4,5-trispho-
sphate (PIP3). But the role of PTEN in miR-21 inducing EMT
and CSC phenotype remains to be elucidated. It is well known
that PTEN negatively regulates the PI3K-protein kinase B
(AKT) pathway [30]and mitogen-activated protein kinase
(MAPK)/extracellular signal regulated kinase1/2 (ERK1/2)
pathway [31], as well as both AKT and ERK1/2 pathways
were considered to be relevant to the maintenance of EMT and
CSC characteristics [32–36].
These results strongly suggest that miR-21 might via AKT and
ERK1/2 pathways by targeting PTEN regulate EMT and CSC
phenotype. In the present study, we have revealed that antagonism
of miR-21reversed EMT consistent with CSC phenotype via AKT
and ERK1/2 pathways by targeting PTEN, indicates a molecular
pathway which might relieve the malignant biological behaviors of
breast cancers.
Results
Transfected hsa-miR-21 Antagomir Decreased the
Expression of miR-21 in MDA-MB-231 Cells
To explore whether hsa-miR-21 antagomir can decrease the
expression of miR-21, hsa-miR-21 antagomir or its negative
control was transfected into MDA-MB-231 cells for 48 h, then the
relative expression of miR-21 was measured by real time RT-
PCR. The relative expression of miR-21 was 0.1071160.01272 in
MDA-MB-231/anti-miR-21 cells, which was significantly down-
regulated, as compare to 1.0786260.09722 in negative control
groups (p=0.0015; Fig. 1A). The results suggested that hsa-miR-
21 antagomir could decrease the expression of miR-21 in MDA-
MB-231 cells.
Antagonism of miR-21 Reversed EMT, as well as
Decreased Migration and Invasion in MDA-MB-231 Cells
To investigate the effects of forced antagonism of miR-21 on the
EMT process of MDA-MB-231 cells, the relative mRNA and
protein expression of mesenchymal phenotype cell biomarkers (N-
cadherin, Vimentin, and alpha-SMA), and epithelial phenotype
cell biomarker (E-cadherin) in MDA-MB-231/anti-miR-21 cells
and corresponding control cells were measured. Antagonism of
miR-21 decreased the relative mRNA levels of N-cadherin,
Vimentin, and alpha-SMA (p=0.0038, p=0.0018, and
p=0.0023, respectively; Fig. 1B, C, D), while increased the
relative mRNA level of E-cadherin (p=0.0017; Fig. 1E) in MDA-
MB-231/anti-miR-21 cells, as compared to corresponding control
cells, by real time RT-PCR analysis. The results suggested that
antagonism of miR-21 could decrease the mRNA expression of
mesenchymal phenotype cell biomarkers, while increase the
mRNA expression of epithelial phenotype cell biomarker. The
results from Western blot analysis demonstrated that the relative
protein levels of N-cadherin, Vimentin, and alpha-SMA were
down-regulated significantly (p=0.0003, p=0.0026, and p=0.04,
respectively; Fig. 1F, G), while that of E-cadherin was up-regulated
significantly (p=0.0053; Fig. 1F, G) in MDA-MB-231/anti-miR-
21 cells, as compared to control cells. The results suggested that
antagonism of miR-21 could decrease the protein expression of
mesenchymal phenotype cell biomarkers, while increase that of
epithelial phenotype cell biomarker. These results clearly demon-
strated that antagonism of miR-21 could reverse the EMT, relying
on inhibit EMT phenotypic biomarkers. Functionally, the relative
migrated and invaded cell numbers of MDA-MB-231/anti-miR-
21 cells were significantly inferior to negative control (p,0.0001,
p,0.0001, respectively; Fig. 1H, I), suggested that antagonism of
miR-21 could reduce cell migration and invasion in MDA-MB-
231 cells, which further emphasized the function of miR-21 in the
invasion and metastasis of breast cancer cells.
Antagonism of miR-21 Reversed CSC Phenotype in MDA-
MB-231 Cells
To examine the effects of antagonism of miR-21 on CSC
phenotype in MDA-MB-231 cells, the proportion of cells with
ALDH1
+ (ALDH
bright) and CD44
+/CD24
2/low in MDA-MB-
231/anti-miR-21 cells and negative control cells were measured.
The percentage of cells with ALDH1
+ in MDA-MB-231/anti-
miR-21 cells was 0.8560.092, significantly less than 2.32360.315
in negative control groups (p=0.0051; Fig. 2A, B), by ALDE-
FLUOR assay; the percentage of cells with CD44
+/CD24
2/low in
MDA-MB-231/anti-miR-21cells was 0.54360.129, also signifi-
cantly lower than 4.80761.062 in control groups (p=0.0094;
Fig. 2C, D), by FACS analysis. These results suggested that
antagonism of miR-21 could decrease the breast cancer CSC
proportion, which expressing CSC surface biomarkers ALDH1
+
and CD44
+/CD24
2/low. Moreover, the relative mRNA and
protein expression of ALDH1 and CD44 in MDA-MB-231/anti-
miR-21 cells and control cells were also measured. The relative
mRNA levels of ALDH1 and CD44 in MDA-MB-231/anti-miR-
21 cells were significantly decreased as compared to control groups
(p=0.0039, p=0.0034, respectively; Fig. 2E, F), as assessed by
real time RT-PCR analysis, which suggested that antagonism of
miR-21 could decrease the mRNA expression of ALDH1 and
CD44. The protein expression of ALDH1 and CD44 were also
decreased accordingly (p=0.0002, p=0.0005, respectively;
Fig. 2G, H), by Western blot analysis, suggested that antagonism
of miR-21 could decrease the protein expression of ALDH1 and
CD44. These results indicated that antagonism of miR-21 could
reverse CSC phenotype in MDA-MB-231 cells, which further
suggested that miR-21 could involve in the regulation of CSC
characteristics. More interestingly, the mammosphere number in
MDA-MB-231/anti-miR-21 cells was significantly inferior to
control groups (p=0.0017; Fig. 2I, J), indicated that antagonism
of miR-21 could decrease formation of mammospheres, which
further suggested that miR-21 could regulate CSC characteristics,
including the capacities of self-renewal and clonogenicity.
Antagonism of miR-21 Induced Over-expression of PTEN
Recent studies have demonstrated that miR-21 increased cell
proliferation, migration and invasion through modulating tumor
suppressor gene PTEN [20], but the role of PTEN in miR-21
regulating tumor EMT and CSC phenotype remains to be
elucidated. To explore whether antagonism of miR-21 regulate
PTEN expression, the mRNA and protein levels of PTEN were
measured, by real time RT-PCR analysis and Western blot
assay, respectively. As expected, both the mRNA and protein
expression of PTEN in MDA-MB-231/anti-miR-21 cells were
strongly up-regulated, as compared to control groups (p=0.003,
p=0.0437, respectively; Fig. 3A, B, D). These results demon-
strated that antagonism of miR-21 could up-regulate the
expression of PTEN.
Antagonism of miR-21 Inactivated AKT and ERK1/2
AKT and ERK1/2 are two major signaling pathways in
regulating cell proliferation, migration and survival, and both
also were regulated by PTEN, but the roles of AKT and
ERK1/2 pathways in miR-21 regulating tumor EMT and CSC
phenotype remains to be elucidated. To determine the signaling
The Mechanism of miR-21 Mediates EMT and CSC
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EMT and CSC phenotype, the protein levels of phosphorylated
AKT (p-AKT) and AKT, phosphorylated ERK1/2 (p-ERK1/2)
and ERK1/2 were measured by Western blot analysis. The
protein levels of p-AKT and p-ERK1/2 in MDA-MB-231/anti-
miR-21 cells were strongly decreased as compared to control
groups (p=0.0173, p=0.0126, respectively; Fig. 3C, D),
confirmed that antagonism of miR-21 could suppress AKT
and ERK1/2 activation in process of reversing EMT and CSC
phenotype.
Re-expression of miR-21 Induced EMT and CSC
Phenotype, Accompanied with Down-expression of
PTEN, as well as Activation of AKT and ERK1/2
To further confirm the role of miR-21 in regulating tumor
EMT and CSC phenotype, hsa-miR-21 mimics or mimics
negative control was transfected into established MDA-MB-231/
anti-miR-21 cells. The expression of miR-21 increased to more
than 22-fold after hsa-miR-21 mimics treated, as compared to
the negative control (p=0.0037; Fig. 4A), indicated that hsa-
miR-21 mimics transfection could increase the relative expression
of miR-21.
To examine whether forced re-expression of miR-21 can induce
EMT and CSC phenotype, down-regulate expression of PTEN, as
well as activate AKT and ERK1/2 pathways, the protein
expression of EMT biomarkers (N-cadherin, Vimentin, alpha-
SMA, and E-cadherin), CSC markers (ALDH1 and CD44),
PTEN, p-AKT, AKT, p-ERK1/2, and ERK1/2 were measured
by Western blot assay. As compared to the negative control
groups, forced re-expression of miR-21 increased the protein
expression of N-cadherin, Vimentin, alpha-SMA, ALDH1 and
CD44 (p=0.0136, p=0.0397, p=0.0067, p=0.0002, and
p=0.0006, respectively; Fig. 4B, C, F), while decreased the
expression of E-cadherin (p=0.0014; Fig. 4B, F), suggested that
re-expression of miR-21 could induce EMT and CSC phenotype
in established MDA-MB-231/anti-miR-21 cells. Meanwhile, re-
expression of miR-21 decreased the expression of PTEN
(p=0.0081; Fig. 4D, F), demonstrated that re-expression of
miR-21 could affect the expression of miR-21 direct target in
the cells. Furthermore, re-expression of miR-21 also increased the
expression of p-AKT and p-ERK1/2 in the cells (p=0.0008,
p=0.0022, respectively; Fig. 4E, F), indicated that re-expression of
miR-21 could activate AKT and ERK1/2 pathways. These results
supported that miR-21 could regulate EMT and CSC phenotype,
Figure 2. Antagonism of miR-21 reversed CSC phenotype. (A, B) ALDH1 enzymatic activity (ALDH
bright) in established breast cancer MDA-MB-
231/anti-miR-21 cells and MDA-MB-231/control cells (n1=n2=3) were detected using the ALDEFLUOR assay. (C, D) The CD44
+/CD24
2/low phenotype
in indicated cells (n1=n2=3) were detected by FACS analysis. (E, F) The relative mRNA levels of ALDH1 and CD44 were detected by real time RT-PCR
assay. (G, H) The relative protein levels of ALDH1 and CD44 were detected by Western blot analysis. Beta-actin was used as loading control. (I, J) The
number of mammospheres from 1000 MDA-MB-231/anti-miR-21 cells or MDA-MB-231/control cells was counted under microscope. All the data
represent at least three experiments done in triplicate. (*indicates p,0.05;
w indicates p,0.001).
doi:10.1371/journal.pone.0039520.g002
The Mechanism of miR-21 Mediates EMT and CSC
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39520and accompany with alterations of PTEN and AKT/ERK1/2
pathways.
MiR-21 Targeted PTEN in Reversing EMT and CSC
Phenotype
To determine whether depletion of PTEN can block miR-21
antagomir reversing EMT and CSC phenotype, siPTEN or the
control SsiPTEN was transfected into MDA-MB-231 cells. After
24 h, the cells were transfected with miR-21 antagomir or negative
control, and then EMT and CSC phenotype were examined as
described above. We found that siPTEN significant down-
regulated the expression of PTEN (p=0.002; Fig. 5A, E), as
compared to SsiPTEN groups. Consistent with the effects of miR-
21 antagomir on EMT and CSC phenotype in MDA-MB-231
cells (Fig. 1 and Fig. 2), antagonism of miR-21 also reversed EMT
(N-cadherin, p=0.0025; Vimentin, p=0.0025; alpha-SMA,
p=0.0003; E-cadherin, p=0.0308; Fig. 5B, E) and CSC
phenotype (ALDH1, p=0.0014; CD44, p=0.002; Fig. 5C, E) in
MDA-MB-231/SsiPTEN cells (SsiPTEN+miRNA antagomir negative
control groups vs. SsiPTEN+miR-21 antagomir groups); depletion of
PTEN by siPTEN blocked miR-21-antagomir-reversing EMT (N-
cadherin, p=0.0172; Vimentin, p=0.0113; alpha-SMA,
p=0.0015; E-cadherin, p=0.016; Fig. 5B, E) and CSC phenotype
(ALDH1, p=0.0042; CD44, p=0.0004; Fig. 5C, E) (SsiPTEN +
miR-21 antagomir groups vs. siPTEN + miR-21 antagomir groups). These
results suggested that depletion of PTEN could block miR-21-
antagomir -reversing EMT and CSC phenotype, which further
suggested that antagonism of miR-21 could target PTEN to
reversing EMT and CSC phenotype. Moreover, depletion of
PTEN activated miR-21-antagomir-blocking AKT and ERK1/2
pathways (p-AKT, p,0.0001; p-ERK1/2, p=0.0037; Fig. 5D, E)
(SsiPTEN + miR-21 antagomir groups vs. siPTEN + miR-21 antagomir
groups), indicated that AKT and ERK1/2 pathways are down-
stream pathways of PTEN in regulating EMT and CSC
phenotype.
MiR-21 Regulated EMT and CSC Phenotype, as well as
Cell Proliferation through AKT and ERK1/2 Pathways
To further investigate the roles of AKT and ERK1/2 pathways
in miR-21 regulating EMT and CSC phenotype, the MDA-MB-
231/anti-miR-21 cells were transfected with miR-21 mimics at
a concentration of 40 nmol for 72 h, and then the cells were
treated with LY294002 (the inhibitor of PI3K-AKT) at 20 mmol/l
or U0126 (the inhibitor of ERK1/2) at 10 mmol/l for 24 h. We
confirmed that LY294002 treatment blocked re-expression of
miR-21 inducing AKT activation (p,0.0001; Fig. 6A, E), while
U0126 treatment abolished re-expression of miR-21 inducing
ERK1/2 activation (p,0.0001; Fig. 6A, E). More interestingly, re-
expression of miR-21 inducing EMT and CSC phenotype were
inhibited by LY294002 (N-cadherin, p=0.0005; Vimentin,
p=0.0005; alpha-SMA, p=0.0008; E-cadherin, p=0.0002;
ALDH1, p,0.0001; CD44, p,0.0001; Fig. 6B, C, E) or U0126
(N-cadherin, p,0.0001; Vimentin, p=0.0005; alpha-SMA,
p=0.0004; E-cadherin, p=0.0003; ALDH1, p,0.0001; CD44,
p=0.0005; Fig. 6B, C, E) in the cells, indicated that both AKT
and ERK1/2 pathways are requiring for miR-21 in inducing
EMT and CSC phenotype, which further suggested that AKT and
ERK1/2 pathways are two parallel downstream pathways of miR-
21 for regulating EMT and CSC phenotype. Furthermore, both
LY294002 and U0126 have no proven effect on PTEN
Figure 3. Antagonism of miR-21 induced the expression of PTEN, as well as inactivated AKT and ERK1/2. (A) Ectopic expression of PTEN
mRNA in MDA-MB-231/anti-miR-21 cells and MDA-MB-231/control cells were verified by real time RT-PCR assay (p=0.003). (B, C, D) Protein levels of
PTEN, p-AKT, AKT, p-ERK1/2, and ERK1/2 in indicated cells were detected by Western blot analysis, and bands were semi-quantified using ImageJ
software. GAPDH was used as loading control. (*indicates p,0.05).
doi:10.1371/journal.pone.0039520.g003
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supported that AKT and ERK1/2 pathways are downstream
pathways of PTEN.
Besides, to verify the roles of AKT and ERK1/2 pathways in
miR-21 regulating cell proliferation in the cells that mentioned
above, the cell growth numbers of the cells were calculated at 0,
12, 24, 36, 48, 60 and 72 h after treatments by cell count. We
found that forced antagonism of miR-21 decreased cell pro-
liferation in MDA-MB-231 cells (p=0.0077; Fig. 6F), while re-
expression of miR-21 elevated cell proliferation in MDA-MB-231/
anti-miR-21 cells, during 0–72 h (p=0.0091; Fig. 6F). The results
suggested that miR-21 could regulate the cell propagation to
a certain degree in MDA-MB-231 cells. Meanwhile, both AKT
and ERK1/2 inhibitions were decreased cell proliferation
(p=0.0109, p=0.0031, respectively; Fig. 6F), which suggested
that the regulation of AKT or ERK1/2 linked to changes in cell
proliferation.
Discussion
MiRNAs are noncoding small RNAs that may act as oncogenes
or tumor suppressor genes [37,38]. Growing evidence showed that
miR-21 over-expression is detected in various kinds of human
cancers including breast cancer, and is associated with EMT [25–
27] and CSC characteristics [26,28]. But the direct roles and
central molecular mechanisms of miR-21 in regulating breast
cancer EMT and CSC phenotype remains to be elucidated. In this
study, we found that antagonism of miR-21 in MDA-MB-231 cells
reversed EMT and CSC phenotype, up-regulated the expression
of PTEN, as well as inactivated AKT and ERK1/2 pathways. The
results demonstrated that antagonism of miR-21 is sufficient to
reverse EMT and CSC phenotype through modulating the
expression of PTEN and AKT/ERK1/2 pathways, providing
some direct evidence and molecular mechanisms that miR-21 is
able to regulate EMT and CSC phenotype.
To investigate the role of miR-21 in regulating EMT and CSC
phenotype of breast cancer cells, antagomir of miR-21, which can
specifically bind to and inhibit endogenous miR-21 molecules, or
its negative control oligomer, was transfected into MDA-MB-231
cells. The antagomir decreased 90% of endogenous miR-21
expression in the cells (Fig. 1A). Interestingly, the relative EMT
and CSC phenotype were reversed by antagonism of miR-
21(Fig. 1B–G; Fig. 2A–J), which consistent with miR-21 involves
in promoting EMT and (or) CSC phenotype in pancreatic cancer
cells [26,28], thyroid carcinoma cells [27], and our previously
study in MCF-7 cells [29]. Accompanied with the results,
antagonism of miR-21 significantly increased the expression of
PTEN (Fig. 3A, B, D), as well as decreased AKT and ERK1/2
activation (Fig. 3C, D). These results demonstrated that miR-21
plays an important role in mediating EMT and CSC phenotype,
accompany by regulating the expression of PTEN, as well as AKT
and ERK1/2 activation.
Next, we explored the underlying mechanisms and relative
signaling molecules in antagonism of miR-21 reversing EMT and
CSC phenotype. In consistent with that miR-21 suppresses the
Figure 4. Hsa-miR-21 mimics induced EMT and CSC phenotype, accompanied with PTEN down-regulation and AKT/ERK1/2
activation. Established MDA-MB-231/anti-miR-21 cells were transfected with hsa-miR-21 mimics at a concentration of 40 nmol for 72 h. (A) MDA-
MB-231/anti-miR-21 cells were treated with hsa-miR-21 mimics elevated the expression of miR-21, as compared to control groups (n1=n2=3;
p=0.00373), by real-time RT-PCR analysis. (B-F) Protein levels of mesenchymal markers (N-cadherin, Vimentin and alpha-SMA) (B), epithelial marker (E-
cadherin) (B), CSC markers (ALDH1 and CD44) (C), PTEN (D), p-AKT and AKT (E), as well as p-ERK1/2 and ERK1/2 (E) in indicated cells were measured by
Western blot analysis, and bands were semi-quantified using ImageJ software (F). Beta-actin or GAPDH was used as loading control. (*indicates
p,0.05;
w indicates p,0.001).
doi:10.1371/journal.pone.0039520.g004
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UTR [20], we proved that antagonism of miR-21 up-regulated
PTEN expression (Fig. 3A, B, D). As expected, PTEN down-
expression notably blocked miR-21-reversing EMT and CSC
phenotype (Fig. 5B, C, E), confirmed that antagonism of miR-21
exhibits its role partly by promoting PTEN expression, and the
recovery of PTEN expression would reduce its function of tumor
suppressor.
Furthermore, we also found that re-expression of miR-21 by
miR-21 mimics led to the activation of AKT and ERK1/2
pathways (Fig. 4E, F). More interestingly, treated the cells with
PI3K-AKT or ERK1/2 inhibitor (LY294002 or U0126), prohib-
ited miR-21 mimics regaining EMT and CSC phenotype (Fig. 6B,
C, E). The results suggested that the effects of AKT and (or)
ERK1/2 on miR-21-regulating EMT and CSC phenotype, in
accordance with that AKT and (or) ERK1/2 pathways are
required for promote EMT and (or) CSC phenotype in breast
cancer MCF-7 cells [32], breast epithelial cells [33,34], colon
cancer cells [35], cervical cancer cells [32], and ovarian
carcinomas cells [36].
In summary, our results demonstrated that antagonism of miR-
21 reverses EMT and CSC phenotype through AKT and ERK1/
2 pathways inactivation by inducing PTEN expression in MDA-
MB-231 cells (Fig. 7). This study showed a direct role and novel
mechanism of miR-21 in inversing EMT and CSC phenotype,
and the information may be useful to develop a new therapy for
treatment of breast cancers in the future.
Materials and Methods
Reagents and Antibodies
Human has-miR-21 (MIMAT0000076) antagomir and negative
control, mimics and negative control were purchased from
Ribobio (Guangzhou, China). The PCR primers were synthesized
by Sangon Biotech (Shanghai, China). Real time RT-PCR assay
kits were purchased from Takara (Dalian, China). Specific siPTEN
duplexes and scramble control siRNA sequence (SsiPTEN) were
purchased from Ribobio. LY294002 and U0126 were purchased
from Sigma (St. Louis, MO, USA). Lipofectamine
TM2000 was
purchased from Invitrogen (Carlsbad, CA, USA). ALDEFLUORH
Kit was purchased from Aldagen (Durham, NC, USA). Fluores-
cein isothiocyanate (FITC)-labeled anti-CD44 antibody and
phycoerythrin (PE)-labeled anti-CD24 antibody were purchased
from BioLegend (San Diego, CA, USA). Primary antibodies
including rabbit antihuman E-cadherin antibody (No: BS1098;
Bioworlde, St. Louis, MO, USA), N-cadherin antibody (No:
Figure 5. PTEN was the downstream target of miR-21 during reversing EMT and CSC phenotype. MDA-MB-231 cells were transfected
with siPTEN or the scrambled control SsiPTEN at a final concentration of 50 nmol for 24 h. Then the cells were transfected with hsa-miR-21 antagomir
or negative control at a final concentration of 50 nmol for 72 h. Cells were trypsinized, and the relative protein levels of PTEN (A), EMT markers (B),
CSC surface markers (C), p-AKT and AKT (D), as well as p-ERK and ERK (D) were measured and semi-quantified (E) as stated before. The representative
plugs from treatments of SsiPTEN plus miR-21 antagomir control, SsiPTEN plus miR-21 antagomir, and siPTEN plus miR-21 antagomir were shown in
the picture. Beta-actin or GAPDH was used as loading control. (*indicates p,0.05;
w indicates p,0.001).
doi:10.1371/journal.pone.0039520.g005
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39520Figure 6. MiR-21 regulated EMT and CSC phenotype through mediating AKT and ERK1/2 activation. Established MDA-MB-231/anti-miR-
21 cells were transfected with hsa-miR-21 mimics at a concentration of 40 nmol for 72 h. Then the cells were trypsinized, and treated with LY294002
(20 mmol/l) or U0126 (10 mmol/l) for 24 h. (A-E) The relative protein levels of p-AKT and AKT (A), p-ERK and ERK (A), EMT markers (B), CSC surface
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alpha-SMA antibody (No: ab5694; Abcam, Cambridge, UK),
ALDH1 antibody (No: ab51028; Abcam), CD44 antibody (No:
BA0321; Boster, Wuhan, China), PTEN antibody (No: BS1304;
Bioworlde), AKT antibody (No: BS1810; Bioworlde), phospho-
AKT (p-AKT) antibody (No: BS4006; Bioworlde), ERK1/2
antibody (No: BS3628; Bioworlde), phospho-ERK1/2 (p-ERK1/
2) antibody(No: BS4621; Bioworlde), GAPDH antibody (No:
AP0063; Bioworlde) and beta-actin antibody (No: BA2305;
Boster), and HRP-conjugated anti-rabbit IgG secondary antibody
(No: BA1055; Boster) were used for Western blot analysis.
Cell Culture
Human breast cancer MDA-MB-231 cells were maintained in
high-glucose DMEM supplemented with 5% FBS (Gibico, Grand
Island, NY, USA), 100 units/ml penicillin, 100 mg/ml streptomy-
cin and 1% glutamine (Invitrogen). Cells were grown at 37uCi na n
atmosphere containing 5% CO2.
Antagonism and Re-expression of miR-21
5610
5 cells were seeded in six-well plates and grown to 60%
confluence. Human has-miR-21 (MIMAT0000076) antagomir or
its negative control was directly transfected into MDA-MB-231
cells at a final concentration of 50 nmol/l, according to the
manufacturer’s protocol. Human has-miR-21 (MIMAT0000076)
mimics or its negative control was allowed to form transfection
complexes with Lipofectamine
TM2000 in free of serum Opti-
MEMH I (Invitrogen) at a final concentration of 40 nmol/l,
according to the manufacturer’s protocol.
Real Time RT-PCR Analysis
For miR-21, the miR-21 reverse transcription (RT) primer (59-
GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTG-
GATACGACTCAACA-39) and real time RT-PCR primers
(Forward: 59-GCCCGCTAGCTTATCAGACTGATG-39; Re-
verse: 59-GTGCAGGGTCCGAGGT-39) were synthesized by
Sangon Biotech. MiRNAs was extracted from cells using
a mirVana miRNA Isolation Kit (Applied Biosystems, Foster
City, CA, USA). SYBR Green–based real time RT-PCR was
performed using SYBRH PrimeScriptH miRNA RT-PCR Kit
(Takara) to measure the expression of mature miR-21 in cells by
a MiniOpticon
TM Two-Color Real-Time PCR Detection System
(Bio-Rad, Hercules, CA, USA). U6 was used as endogenous
control.
For mRNAs, total RNA from cells was isolated using TRIzol
reagent (Invitrogen). Real time RT-PCR reactions were carried
out using SYBRH Premix Ex Taq
TM II (Takara). Beta-actin was
used as endogenous control.
Western Blot Analysis
Western blot analysis was conducted as our previously study
[29,39]. Briefly, the protein was separated by SDS-PAGE (8%,
10%, or 12%) and transferred to PVDF membranes. Nonspecific
binding sites were blocked by incubating with TBST containing
5% (w/v) non-fat dried milk. Then incubated with primary
antibodies (as described above) and HRP-conjugated anti-rabbit
IgG secondary antibody in order, and visualized by ECL
chemiluminescence. Beta-actin or GAPDH was used as loading
control. The bands were semi-quantified using ImageJ software.
Migration and Invasion Assays
Cell migration and invasion assays were performed as our
previously described [29,40]. For invasion assay, 2.5610
4 cells
were seeded on an 8-mm pore size Transwell insert (Corning Inc.
Corning, NY, USA) coated with ECM (1:7.5) (Sigma), while cell
migration assay did not coat with ECM. After 24 h of incubation
at 37uC in an atmosphere containing 5% CO2, the cells adherent
to the upper surface of the filter were removed using a cotton
applicator. Then cells were stained with 0.4% crystal violet
dissolved in methanol, and the numbers of cells on the bottom
were counted.
ALDEFLUOR Assay
The ALDEFLUOR kit was used to isolate the population with
high ALDH1enzymatic activity (ALDH
bright) as previously de-
scribed [13,29]. Briefly, cells were incubated in ALDEFLUOR
assay buffer containing ALDH substrate bodipy-aminoacetalde-
hyde (BAAA, 1 mmol/l). In each experiment, a sample of cells was
stained under identical conditions with diethylaminobenzaldehyde
(DEAB), a specific ALDH inhibitor, as negative control. Flow
cytometry (FACS) analysis was used to measure ALDH
bright cell
subpopulation.
FACS of CD44
+/CD24
2/low Cell Subpopulation
FACS of CD44
+/CD24
2/low cell subpopulation was performed
as our previously described [29,40]. Briefly, at least 1610
5 unfixed
cells were incubated with FITC-labeled anti-CD44 antibody and
markers (C), as well as PTEN (D) from blank control, LY294002, and U0126 treatment groups were shown, and semi-quantified (E) as stated before.
Beta-actin or GAPDH was used as loading control. (*indicates p,0.05;
w indicates p,0.001;
m indicates p.0.05). (F) The effects of antagonism of miR-
21, re-expression of miR-21, LY294002, and U0126 on cell proliferation by cell count (A vs. B, p=0.0077; B+C vs. B+D, p=0.0091; B+D vs. B+D+E,
p=0.0109; B+D vs. B+D+F, p=0.0031).
doi:10.1371/journal.pone.0039520.g006
Figure 7. Schematic diagram of the proposed model: possible
mechanism of miR-21 regulates EMT and CSC phenotype.
Antagonism of miR-21 could inactivate AKT and ERK1/2 pathways
presumably through PTEN up-regulation, and finally reverse EMT and
CSC phenotype in MDA-MB-231 cells.
doi:10.1371/journal.pone.0039520.g007
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Then the cells were analyzed by a FACScalibur flow cytometer
(BD Biosciences, Franklin Lakes, NJ, USA) using CellQuest
software.
Mammosphere Formation Assay
Mammosphere formation assay was performed as described
previously [12,13,29]. Density of 5610
3–1610
4 cells per milliliter
single-cell suspensions were seed into six-well non-adherent plates
in serum-free DMEM/F12 (Gibico) supplemented with 2% B27
(Invitrogen), 20 ng/ml EGF (PeproTech, London, UK), 20 ng/ml
bFGF (PeproTech), 0.4% BSA (Sigma), and 5 mg/ml insulin. After
7 day of culture, the numbers of mammospheres were counted.
Construction of siPTEN
Based on human PTEN mRNA sequence (NM_000314),
specific siRNA duplexes were designed, synthesized and annealed
by Ribobio. The selected RNA duplex (siPTEN) corresponding to
nucleotides 1567–1585 of PTEN mRNA is defined as sense: 59-
GCUACCUGUUAAAGAAUCAdTdT-39 and antisense: 59-
UGAUUCUUUAACAGGUAGCdTdT-39. The scramble control
siRNA sequence (SsiPTEN) was also designed by Ribobio, and has
no significant homology to any known human gene sequence.
Transfection of siPTEN
5610
5 cells were seeded in six-well plates and grown to 70%
confluence. Human siPTEN or SsiPTEN was allowed to form
transfection complexes with Lipofectamine
TM2000 (Invitrogen) in
free of serum Opti-MEMH I (Invitrogen) at a final concentration of
50 nmol/l, according to the manufacturer’s protocol.
Cell Proliferation Assay
Various cells were cultured in 10% FBS culture medium as
mentioned in Cell Culture part. The cell growth numbers of the
cells were calculated and analyzed by cell count at 0, 12, 24, 36,
48, 60 and 72 h after treatments.
Statistical Analysis
All data were expressed as mean 6 SD and were calculated by
using statistics analysis software SPSS 13.0. Statistical difference of
each treatment was compared by Student’s t test. The P value
equal to or less than 0.05 was considered as statistical significance.
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